FUJIREBIO-EUROPE
23.6.2022 09:41:07 CEST | Business Wire | Press release
H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio Holdings, Inc., and ADx NeuroSciences NV today announced the acquisition of ADx NeuroSciences by Fujirebio for 40 million euros. Pending the satisfaction of customary closing conditions, the deal is expected to close in July 2022. ADx NeuroSciences becomes a wholly owned subsidiary of Fujirebio Europe NV.
“ By welcoming ADx NeuroSciences in the Fujirebio group of companies, Fujirebio will be able to expand its antibody supply business and contract development and manufacturing (CDMO) offerings in the neurodegenerative field to our partners globally,” says Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. “Fujirebio is committed to invest in developing diagnostic kits in the field of neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. We are excited to work together with the ADx NeuroSciences team to expand the global neurodegeneration biomarker testing market.”
“It is a unique opportunity for us to completely integrate the CDMO-based open platform strategy of Fujirebio in this way,” states Koen Dewaele, CEO of ADx NeuroSciences. “Our partners will benefit from the synergies between our teams and the speed with which we can bring our antibodies and assays to the diagnostics industry and on various platforms, all under the high-quality mark of excellence for which Fujirebio has become well known.”
ADx NeuroSciences specializes in generating tailor-made antibodies and developing assays for pharma and in vitro diagnostics (IVD) companies. As part of Fujirebio, ADx NeuroSciences will continue to serve its current partners and customers in their diagnostic biomarker development and will continue to expand its extensive portfolio of state-of-the-art biomarkers and antibodies to help detect neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. Its current pipeline encompasses, next to several phospho-tau specific antibodies for measurement in plasma, biomarkers targeting synaptic degeneration supporting prognosis of these devastating diseases.
Fujirebio is a trusted partner for high-quality IVD testing solutions and a historical pioneer in neurodegenerative disease diagnostics. The company will combine the unique know-how and biomarker portfolio of ADx NeuroSciences with both its own solid experience in bringing high quality IVD products to the market and its strategic CDMO partnerships that make unique testing solutions available to the entire diagnostics industry. The acquisition also concentrates considerable additional know-how, expertise, and resources in the Fujirebio Neuro Center of Excellence.
About Fujirebio
Fujirebio, a member of H.U. Group Holdings Inc., whose name represents “Healthcare for you” and which is a listed company on Tokyo Stock Exchange (TSE: 4544), is a global leader in the field of high-quality IVD testing. Founded in 1950, it has more than 50 years’ accumulated experience in the conception, development, production, and worldwide commercialization of robust IVD products. With Fujirebio Holdings Inc., located in Tokyo, Japan, its subsidiaries are located in Japan, US and Europe.
Fujirebio was the first company to develop and market CSF biomarkers for Alzheimer’s disease testing, under the Innogenetics brand, over 25 years ago. Fujirebio remains the only company with such a comprehensive line-up of manual and fully automated AD assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier, and more complete neurodegenerative diagnostic tools.
About ADx NeuroSciences
ADx NeuroSciences is an R&D driven company specialized in the development of neurodegenerative biomarkers. Its expertise is used by pharmaceutical and diagnostic companies for the conception, development, production, and worldwide commercialization of novel biomarkers.
ADx NeuroSciences was founded in 2011 and is now working with the top pharmaceutical and diagnostic companies in US, Europe, Japan, and China. These collaborations result in new diagnostic assays that support the development of promising drugs either by monitoring the drug effect or by selecting the right patients at a very early stage of the disease. These assays are used in neurodegenerative diseases like Alzheimer’s disease and Parkinson’s and can be applied to a variety of platforms for research up to IVD use.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005429/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
bet365 Partners with TestMu AI to Accelerate Global Release Velocity with Agentic AI Quality Engineering31.3.2026 19:01:00 CEST | Press release
Streamlines Hillside Technology testing across browsers and mobile devices while supporting rapid expansion into regulated markets. TestMu AI (Formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, today announced that Hillside Technology Limited, the technology powerhouse behind global online gambling leader bet365, has adopted its platform to unify software testing and support hundreds of weekly production releases. The global online gaming industry is currently experiencing a massive shift, with the market projected to exceed $150 billion by 2030. As mobile gaming becomes the primary touchpoint for users, the technical complexity of delivering a seamless, low-latency experience has grown exponentially. For industry giants like bet365, the need to validate software across an infinite matrix of hardware, screen resolutions, and OS versions is a mission-critical requirement. This partnership ensures that, as gaming becomes more mobile-centric, bet36
IFF Secures First Heart Health Claim for Soy Protein in Australia and New Zealand31.3.2026 16:00:00 CEST | Press release
Regulatory milestone opens heart health growth opportunities for food and beverage manufacturers IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and health & biosciences announced today that a new heart health claim for isolated soy protein has been accepted by the Food Standards Australia New Zealand (FSANZ). The approval enables food and beverage manufacturers in Australia and New Zealand to link soy protein consumption with healthy blood cholesterol levels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330523416/en/ First heart health claim approved for soy protein in Australia and New Zealand. “For decades, IFF has invested in the science behind soy protein and its role in supporting cardiovascular health,” said Tony Andrew, vice president of protein solutions for IFF Food Ingredients. “This approved claim validates years of rigorous research and collaboration. With our deep expertise in ing
Sub-Q Bionics Closes $1.5M Pre-Seed Round to Advance Next-Generation Solution for Lymphedema Care31.3.2026 15:26:00 CEST | Press release
Sub-Q Bionics, a medical device company developing next-generation solutions to improve care for patients living with lymphedema, today announced the successful close of its $1.5 million pre-seed funding round. The round includes investment from Mayo Clinic and Yeda, the technology transfer company of the Weizmann Institute of Science, as well as several private investors. The Israel Innovation Authority also provided matching funds. The funding will enable Sub-Q Bionics to continue to develop its novel bionic lymph node technology designed to transform how lymphedema is managed, based on scientific innovations from the Weizmann Institute and Shamir Medical Center. The system aims to provide a solution to manage fluid with a subcutaneous implant that will allow patients freedom of movement, automatic fluid management and reduction of symptoms such as pain and swelling. Lymphedema affects millions of patients worldwide, especially breast cancer survivors, and remains significantly under
HTEC Achieves SOC 2 Type II Attestation, Reinforcing Commitment to Client Trust31.3.2026 15:25:00 CEST | Press release
HTECtoday announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331132225/en/ HTEC today announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. For clients, this means working with a technology partner whose practices are standardized, consistently executed, and independently verified over time. It reflects a level of operational maturity where security, reliability, and data protection are built into every engagement. Achieving this standard required coordinated effort across the entire organization. Compliance, engineering, delivery, security, IT, legal, and people t
Impartner Redefines Partner Marketing Automation with Full Automation, AdTech and AI to Drive Measurable Revenue31.3.2026 15:00:00 CEST | Press release
New automation and AI capabilities connect partner campaigns and engagement directly to pipeline and revenue outcomes. Impartner, the world’s leading partner revenue orchestration platform, today announced a major advancement that unifies partner marketing automation within the platform, powered by full automation, AdTech and AI to turn partner marketing into measurable revenue. As partner ecosystems expand across regions, marketplaces and multi-tier models, marketing execution has often remained fragmented. Impartner eliminates those gaps by unifying recruitment, enablement, campaign automation and performance tracking within a single operational system, making partner demand generation and marketing fully operational, measurable, and scalable across all partner interactions. “What makes partner marketing successful is not content distribution, it’s execution, scale and measurable pipeline and revenue,” said Emile van de Klok, Senior Director of Channel Marketing Solutions at Impartne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom